Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
ICAD Price Action
Last 7 days
-1.7%
Last 30 days
-1.9%
Last 90 days
2.4%
Trailing 12 Months
-12.1%
ICAD RSI Chart
ICAD Valuation
ICAD Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
ICAD Fundamentals
ICAD Revenue
ICAD Earnings
ICAD Profitability
ICAD Investor Care
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 19.5M | 0 | 0 | 0 |
| 2024 | 17.9M | 18.8M | 18.9M | 19.6M |
| 2023 | 18.8M | 15.4M | 15.1M | 17.3M |
| 2022 | 32.5M | 32.3M | 27.3M | 21.9M |
| 2021 | 31.8M | 34.0M | 36.3M | 33.6M |
| 2020 | 31.1M | 29.4M | 28.6M | 29.7M |
| 2019 | 26.1M | 27.2M | 28.9M | 31.3M |
| 2018 | 27.6M | 27.4M | 26.6M | 25.6M |
| 2017 | 27.1M | 26.1M | 27.1M | 28.1M |
| 2016 | 34.4M | 30.6M | 27.0M | 26.3M |
| 2015 | 48.6M | 50.1M | 47.1M | 41.6M |
| 2014 | 33.7M | 35.6M | 39.9M | 43.9M |
| 2013 | 29.9M | 31.6M | 31.8M | 33.1M |
| 2012 | 27.7M | 26.9M | 27.1M | 28.3M |
| 2011 | 25.4M | 25.9M | 28.4M | 28.7M |
| 2010 | 0 | 26.9M | 25.8M | 24.6M |
Get all data in R, Python etc through our Historical Stock Data APIs
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
| CEO | Ms. Dana R. Brown |
|---|---|
| WEBSITE | icadmed.com |
| SECTOR | Healthcare |
| INDUSTRY | Medical Devices |
| EMPLOYEES | 108 |
